HFSA 2025 in Minneapolis: Driving the Next Era of Tricuspid & Device-Based Heart Failure Therapies
The HFSA Annual Scientific Meeting in Minneapolis was not just a gathering of heart failure thought leaders — in 2025, a new “Devices in Heart Failure: From Mechanisms to Implementation” pre-meeting was introduced, underscoring the accelerating role of structural and device therapies in heart failure care.
A Broader Focus: Devices and Implementation
The one-day HFSA Devices meeting, held immediately before the main ASM, featured a rich program of didactic sessions, hands-on experiences, vendor exhibits, and networking opportunities. Key themes included:
- The evolving landscape of device-based therapies in heart failure, including novel decongestion strategies, hemodynamics, and remote patient care
- Interdisciplinary interaction: panels addressed how interventional cardiology and electrophysiology can cross-silo to inform device adoption
- Two signature sessions — Trial Tinder and Heart Tank — enabled device sponsors to present trials (at various stages) to clinicians and potential sites, fostering collaboration and accelerating translation from concept to implementation.
- Hands-on labs with catheterization, LVAD / mechanical support, and demonstrations of device platforms
The new forum amplifies the “how” of bringing technologies into practice, beyond just the scientific rationale.
P&F’s Role and TricValve® Spotlight
Against that backdrop, P&F Products and Features had a strong presence. Across both the Devices meeting and the main HFSA ASM, P&F joined sessions, presented data, and engaged directly with clinicians, trialists, and industry partners, shaping the future of structural heart disease.
A central highlight was the TricValve® Transcatheter Bicaval Valve System. This is a breakthrough device specifically designed to address a significant unmet clinical need in severe tricuspid regurgitation. At HFSA, Rishi Puri, M.D., Ph.D., F.R.A.C.P. (Cleveland Clinic, USA) introduced the TRICAV-I trial design and made the case for how this therapy targets a patient population that has been underserved by existing options.
In the context of HFSA’s devices meeting, TricValve® fits squarely into the emerging paradigm of implementing structural therapies in heart failure. As clinicians and device innovators increasingly intersect, P&F’s contributions help bridge that gap between concept and real-world impact.
Building Momentum for the Future
HFSA’s new Devices meeting signals a maturation in the field — from showing what devices can do, to helping clinicians and systems figure out how to use them. The presence of sessions like Trial Tinder, Heart Tank, and hands-on skill labs supports that transition precisely.
For P&F, this was more than exposure. It was an opportunity to build relationships, inform trial design, and help drive the adoption of novel therapies like TricValve. Looking ahead, the aim is to continue collaborating with clinical leaders and partners to improve outcomes for patients with severe tricuspid regurgitation and structural heart disease more broadly.
For more on the HFSA Annual Scientific Meeting, visit HFSA 2025.
